Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Mallinckrodt
Dow
Moodys
Colorcon

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Litigation Details for Purdue Pharma Products LP v. Par Pharmaceuticals Inc. (D. Del. 2007)

See Plans and Pricing

« Back to Dashboard

Purdue Pharma Products LP v. Par Pharmaceuticals Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-05-09
Court District Court, D. Delaware Date Terminated 2009-08-14
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand None Referred To
Parties BIOVAIL LABORATORIES INTERNATIONAL SRL; NAPP PHARMACEUTICAL GROUP LTD.; ORTHO-MCNEIL INC.; PAR PHARMACEUTICAL COMPANIES INC.; PAR PHARMACEUTICALS INC.; PURDUE PHARMA PRODUCTS LP
Patents 4,389,393; 5,202,128; 5,591,452; 5,708,011; 5,859,021; 6,254,887; 7,074,430
Attorneys Anna Brandl; Daniel G. Brown; Edgar H. Haug; Frederick L. Cottrell , III; Jack B. Blumenfeld; Mary W. Bourke; Nicole W. Stafford; Richard D. Kirk; Robert E. Colletti; Rodger Dallery Smith , II; Stephen M. Ferguson; Steven J. Fineman
Firms Benesch Friedlander Coplan & Aronoff LLP; Womble Carlyle Sandridge & Rice, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Purdue Pharma Products LP v. Par Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Purdue Pharma Products LP v. Par Pharmaceuticals Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-05-09 1 Complaint . .. . 424/38 0338383 10/1989 (h.},) A61w9/54 4,389,393 ()/1983 Schor et ul. . 424/19 , , ., , 4421736…ACTION 1. This is an action for patent infringement arising under the patent laws of the United States, …States patent, including all right to sue and to recover for past infringement thereof, which patent is …United States Patent No. 6,254,887, entitled “CONTROLLED RELEASE TRAMADOL” (“the‘887 patent”), a copy of…, alleging that the ‘887 patent, listed in the FDA’s Orange Book as a patent covering the drug Ultram® External link to document
2008-05-01 124 Answer to Counterclaim described in the ‘887 patent and in U.S. Patent No. 5,591,452 (the “‘452 patent”). Except as expressly…European Patent Office in opposition to European Patent No. 624,366 (“the European ‘366 patent”). The …have been the assignees of U.S. Patent No. 6,254,887 (the “‘887 patent”). Except as expressly admitted…have been the assignees of U.S. Patent No. 7,074,430 (“the ‘430 patent”). Except as expressly admitted…. have been the assignees of the ‘887 patent and the ‘452 patent. Except as expressly admitted, Plaintiffs External link to document
2008-06-13 157 Claim Construction Opening Brief application issued as U.S. Patent No. 5,591,452 (“‘452 patent”). The ‘887 patent in suit is a divisional… of U.S. Patents Nos. 6,254,887 (“‘887 patent”) (Whitney Ex.1 1) and 7,074,430 (“‘430 patent”) (Whitney…claims of the patent, the Court considers the literal language of the claims, the patent specification… The ‘887 patent is titled “Controlled Release Tramadol” and the ‘430 patent is titled “Controlled…31 of the ‘887 patent and claims 1, 3, 5, 6, 7, 11, 12, 13, 14 and 15 of the ‘430 patent. Claim 1 of each External link to document
2008-06-24 169 Redacted Document 1 U.S. Patent Nos. 6,254,887 (“the ’887 patent”) and 7,074,430 (“the ’430 patent”) (collectively…marketed, infringe the ’887 patent or the ’430 patent, and Whether these patents are valid and enforceable…The ’887 patent and the ’430 patent are classic life-cycle management, “line extension” patents concerning…Terms in the ’887 Patent and ’430 Patent The limitations in claim l of the ’887 patent and claim 1 of the…specification of the ’887 patent or ’430 patent, but the prosecution history of the ’887 patent is informative It External link to document
2008-08-08 201 Opening Brief in Support The patents at issue in this case, U.S. Patent Nos. 6,254,887 B1 (“the ’887 patent”) and 7,074,430… Corresponding Issued Patent U.S. Patent No. 5,580,578” (Ex. A at 13); … Prosecution of the ’887 Patent and the ’430 Patent” (id. at 21); and 2 “Ex. _…Prosecution of the ’887 Patent and the ’430 Patent” (id. at 68). Although…-20, 22-27, 29-32 of the ’887 patent and claims 1-17 of the ’430 patent under 35 U. External link to document
2008-08-22 209 Redacted Document United States Patent Nos. 6,254,887 (“the ‘887 patent") and '7,074,430 (“thc ‘430 patent”)l 12 `…THERAPEUTIC EFFEC'I` 29 `i`he ‘887 and ‘430 patents contain no pain studies of any kind and report …ttaltei'i23 ("')~Tr:trnadol is a more patent blocker of norepirtephrine rcuptake than is (+)…'A), (+)-~'1' and (j;)~`[ were more patent nnalgcsics than (»-)»`1', whereas tim incidence…2007 14 August 2009 1:07-cv-00255-KAJ Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Moodys
Baxter
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.